ZA200209438B - Prophylactic and therapeutic treatment of infectious autoimmune and allergic diseases with mono and disaccharide-base compounds. - Google Patents
Prophylactic and therapeutic treatment of infectious autoimmune and allergic diseases with mono and disaccharide-base compounds. Download PDFInfo
- Publication number
- ZA200209438B ZA200209438B ZA200209438A ZA200209438A ZA200209438B ZA 200209438 B ZA200209438 B ZA 200209438B ZA 200209438 A ZA200209438 A ZA 200209438A ZA 200209438 A ZA200209438 A ZA 200209438A ZA 200209438 B ZA200209438 B ZA 200209438B
- Authority
- ZA
- South Africa
- Prior art keywords
- group
- accordance
- independently selected
- alkyl
- members independently
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 64
- 208000015181 infectious disease Diseases 0.000 title claims description 19
- 208000023275 Autoimmune disease Diseases 0.000 title claims description 6
- 230000001225 therapeutic effect Effects 0.000 title description 14
- 230000000069 prophylactic effect Effects 0.000 title description 13
- 238000011282 treatment Methods 0.000 title description 8
- 230000002458 infectious effect Effects 0.000 title description 4
- 208000026935 allergic disease Diseases 0.000 title description 2
- 230000001363 autoimmune Effects 0.000 title description 2
- -1 n-tetradecanoyl Chemical group 0.000 claims description 52
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims description 51
- 125000002252 acyl group Chemical group 0.000 claims description 32
- 125000000217 alkyl group Chemical group 0.000 claims description 30
- 102000004127 Cytokines Human genes 0.000 claims description 25
- 108090000695 Cytokines Proteins 0.000 claims description 25
- 150000003839 salts Chemical class 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 20
- 125000004432 carbon atom Chemical group C* 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 239000000427 antigen Substances 0.000 claims description 13
- 102000036639 antigens Human genes 0.000 claims description 13
- 108091007433 antigens Proteins 0.000 claims description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 102000002689 Toll-like receptor Human genes 0.000 claims description 10
- 108020000411 Toll-like receptor Proteins 0.000 claims description 10
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 9
- 208000035473 Communicable disease Diseases 0.000 claims description 9
- 206010035664 Pneumonia Diseases 0.000 claims description 9
- 239000004094 surface-active agent Substances 0.000 claims description 9
- 229910019142 PO4 Inorganic materials 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 7
- 241000894006 Bacteria Species 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 229910018830 PO3H Inorganic materials 0.000 claims description 5
- 241000233872 Pneumocystis carinii Species 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 4
- LVNGJLRDBYCPGB-UHFFFAOYSA-N 1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-UHFFFAOYSA-N 0.000 claims description 4
- BIABMEZBCHDPBV-MPQUPPDSSA-N 1,2-palmitoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-MPQUPPDSSA-N 0.000 claims description 4
- 206010011409 Cross infection Diseases 0.000 claims description 4
- 206010029803 Nosocomial infection Diseases 0.000 claims description 4
- FVJZSBGHRPJMMA-IOLBBIBUSA-N PG(18:0/18:0) Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-IOLBBIBUSA-N 0.000 claims description 4
- 208000010668 atopic eczema Diseases 0.000 claims description 4
- 230000001580 bacterial effect Effects 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 208000035143 Bacterial infection Diseases 0.000 claims description 3
- 208000008745 Healthcare-Associated Pneumonia Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 230000000172 allergic effect Effects 0.000 claims description 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 3
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 claims description 2
- OZSITQMWYBNPMW-GDLZYMKVSA-N 1,2-ditetradecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCC OZSITQMWYBNPMW-GDLZYMKVSA-N 0.000 claims description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 241000588914 Enterobacter Species 0.000 claims description 2
- 241000588722 Escherichia Species 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 241000588748 Klebsiella Species 0.000 claims description 2
- 241000588769 Proteus <enterobacteria> Species 0.000 claims description 2
- 241000589516 Pseudomonas Species 0.000 claims description 2
- 241000607720 Serratia Species 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 claims description 2
- 229960005160 dimyristoylphosphatidylglycerol Drugs 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- BPHQZTVXXXJVHI-AJQTZOPKSA-N ditetradecanoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-AJQTZOPKSA-N 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 206010027654 Allergic conditions Diseases 0.000 claims 3
- 239000010452 phosphate Substances 0.000 claims 3
- SLKDGVPOSSLUAI-PGUFJCEWSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCC SLKDGVPOSSLUAI-PGUFJCEWSA-N 0.000 claims 2
- YFWHNAWEOZTIPI-DIPNUNPCSA-N 1,2-dioctadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCCCC YFWHNAWEOZTIPI-DIPNUNPCSA-N 0.000 claims 2
- 208000037581 Persistent Infection Diseases 0.000 claims 2
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims 2
- 229910014585 C2-Ce Inorganic materials 0.000 claims 1
- 206010008909 Chronic Hepatitis Diseases 0.000 claims 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims 1
- 241000701806 Human papillomavirus Species 0.000 claims 1
- 208000007027 Oral Candidiasis Diseases 0.000 claims 1
- 229910006069 SO3H Inorganic materials 0.000 claims 1
- 241000191940 Staphylococcus Species 0.000 claims 1
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 208000028169 periodontal disease Diseases 0.000 claims 1
- 230000001932 seasonal effect Effects 0.000 claims 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 22
- 239000002158 endotoxin Substances 0.000 description 19
- 229920006008 lipopolysaccharide Polymers 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 16
- 230000006698 induction Effects 0.000 description 15
- 150000002772 monosaccharides Chemical class 0.000 description 15
- 108090000174 Interleukin-10 Proteins 0.000 description 11
- 206010022000 influenza Diseases 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 108090001005 Interleukin-6 Proteins 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- 230000003308 immunostimulating effect Effects 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 125000001424 substituent group Chemical group 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 229960001438 immunostimulant agent Drugs 0.000 description 8
- 239000003022 immunostimulating agent Substances 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 108090001007 Interleukin-8 Proteins 0.000 description 7
- 239000008215 water for injection Substances 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000009640 blood culture Methods 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000004988 splenocyte Anatomy 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 238000011725 BALB/c mouse Methods 0.000 description 5
- 206010061598 Immunodeficiency Diseases 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 231100000518 lethal Toxicity 0.000 description 5
- 230000001665 lethal effect Effects 0.000 description 5
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000013011 aqueous formulation Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000015788 innate immune response Effects 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 102000004388 Interleukin-4 Human genes 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 150000002016 disaccharides Chemical class 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000003393 splenic effect Effects 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- NEZDNQCXEZDCBI-UHFFFAOYSA-N 2-azaniumylethyl 2,3-di(tetradecanoyloxy)propyl phosphate Chemical compound CCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCC NEZDNQCXEZDCBI-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241001227713 Chiron Species 0.000 description 2
- 241000759568 Corixa Species 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102000052508 Lipopolysaccharide-binding protein Human genes 0.000 description 2
- 108010053632 Lipopolysaccharide-binding protein Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 206010035660 Pneumocystis Infections Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 241000725643 Respiratory syncytial virus Species 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 2
- 101150082427 Tlr4 gene Proteins 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000001668 ameliorated effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 150000008271 glucosaminides Chemical class 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 208000037797 influenza A Diseases 0.000 description 2
- 210000005007 innate immune system Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229940071648 metered dose inhaler Drugs 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000003595 mist Substances 0.000 description 2
- 238000011294 monotherapeutic Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229940031439 squalene Drugs 0.000 description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 125000004417 unsaturated alkyl group Chemical group 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- QFMZQPDHXULLKC-UHFFFAOYSA-N 1,2-bis(diphenylphosphino)ethane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 QFMZQPDHXULLKC-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 102100034112 Alkyldihydroxyacetonephosphate synthase, peroxisomal Human genes 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 241000272478 Aquila Species 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 101001011741 Bos taurus Insulin Proteins 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 241000223203 Coccidioides Species 0.000 description 1
- 108091029430 CpG site Proteins 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 238000011765 DBA/2 mouse Methods 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000799143 Homo sapiens Alkyldihydroxyacetonephosphate synthase, peroxisomal Proteins 0.000 description 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100153375 Mus musculus Tlr4 gene Proteins 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241001068263 Replication competent viruses Species 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 102000008233 Toll-Like Receptor 4 Human genes 0.000 description 1
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000012679 convergent method Methods 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 231100000284 endotoxic Toxicity 0.000 description 1
- 230000002346 endotoxic effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 125000005313 fatty acid group Chemical group 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000004047 hyperresponsiveness Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 230000017307 interleukin-4 production Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 150000008103 phosphatidic acids Chemical class 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 229940067605 phosphatidylethanolamines Drugs 0.000 description 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical class OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229940057847 polyethylene glycol 600 Drugs 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229940051841 polyoxyethylene ether Drugs 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008229 sterile water for irrigation Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000005309 thioalkoxy group Chemical group 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- HHLJUSLZGFYWKW-UHFFFAOYSA-N triethanolamine hydrochloride Chemical compound Cl.OCCN(CCO)CCO HHLJUSLZGFYWKW-UHFFFAOYSA-N 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
PROPHYLACTIC AND THERAPEUTIC TREATMENT OF INFECTIOUS AND
OTHER DISEASES WITH MONO- AND DISACCHARIDE-BASED COMPOUNDS
The innate immune system coordinates the inflammatory response to pathogens by a system that discriminates between self and non-self via receptors that identify classes of molecules synthesized exclusively by microbes. These classes are sometimes referred to as pathogen associated molecular patterns (PAMPs) and include, for example, lipopolysaccharide (LPS), peptidoglycans, lipotechoic acids, and bacterial lipoproteins (BLPs). © LPS is an abundant outer cell-wall constituent from gram-negative bacteria that is recognized by the innate immune system. Although the chemical structure of LPS has been known for some time, the molecular basis of recognition of
LPS by serum proteins and/or cells has only recently begun to be elucidated. In a series of recent reports, a family of receptors, referred to as Toll-like receptors (TLRs), have been linked to the potent innate immune response to LPS and other microbial components. All members of the TLR family are membrane proteins having a single transmembrane domain. The cytoplasmic domains are approximately 200 amino acids and share similarity with the cytoplasmic domain of the IL-1 receptor. The extracellular domains of the Toll family of proteins are relatively large (about 550-980 amino acids) and may contain multiple ligand-binding sites.
The importance of TLRs in the immune response to LPS has been specifically demonstrated for at least two Toll-like receptors, TirZ and Tir4. For example, transfection studies with embryonic kidney cells revealed that human Tlr2 was sufficient to confer responsiveness to LPS (Yang et al., Nature 395:284-288 (1998); Kirschning et al. J Exp Med. 11:2091-97 (1998)). A strong response by LPS appeared to require both the LPS-binding protein (LBP) and CD14, which binds LPS with high affinity. Direct binding of LPS to Tlr2 was observed at a relatively low affinity, suggesting that accessory proteins may facilitate binding and/or activation of
Tir2 by LPS in vivo.
)
The importance of TIr4 in the immune response to LPS was demonstrated in conjunction with positional cloning in /ps mutant mouse strains. Two mutant alleles of the mouse Ips gene have been identified, a semidominant allele that arose in the C3H/HeJ strain and a second, recessive allele that is present in the
C57BL/10ScN and C57BL/10ScCr strains. Mice that are homozygous for mutant alleles of Ips are sensitive to infection by Gram-negative bacteria and are resistant to
LPS-induced septic shock. The Ips locus from these strains was cloned and it was demonstrated that the mutations altered the mouse Tlr4 gene in both instances (Portorak et al., Science 282:2085-2088 (1998); Qureshi et al., J Exp Med 4:615-625 (1999)). It was concluded from these reports that Tlr4 was required for a response to LPS.
The biologically active endotoxic sub-structural moiety of LPS is lipid-
A, a phosphorylated, multiply fatty-acid-acylated glucosamine disaccharide that serves to anchor the entire structure in the outer membrane of Gram-negative bacteria. We previously reported that the toxic effects of lipid A could be ameliorated by selective chemical modification of lipid A to produce monophosphoryl lipid A compounds (MPL® immunostimulant; Corixa Corporation; Seattle, WA). Methods of making and using MPL® immunostimulant and structurally like compounds in vaccine adjuvant and other applications have been described (see, for example, U.S. Patent Nos. 4,436,727; 4,877,611; 4,866,034 and 4,912,094; 4,987,237; Johnson et al., J Med Chem 42:4640-4649 (1999); Ulrich and Myers, in Vaccine Design: The Subunit and Adjuvant
Approach; Powell and Newman, Eds.; Plenum: New York, 495-524, 1995; the disclosures of which are incorporated herein by reference in their entireties). In particular, these and other references demonstrated that MPL® immunostimulant and related compounds had significant adjuvant activities when used in vaccine formulations with protein and carbohydrate antigens for enhancing humoral and/or cell- mediated immunity to the antigens.
Moreover, we have previously described a class of synthetic mono- and disaccharide mimetics of monophosphoryl lipid A, referred to as aminalkyl glucosaminide phosphates (AGPs), for example in U.S. Ser. Nos. 08/853,826, 09/074,720, 09/439,839 and in PCT/US98/09385, the disclosures of which are incorporated herein by reference in their entireties. Like monophosphoryl lipid A, these compounds have been demonstrated to retain significant adjuvant characteristics when formulated with antigens in vaccine compositions and, in addition, have similar or improved toxicity profiles when compared with monophosphoryl lipid A. A significant advantage offered by the AGPs is that they are readily producible on a commercial scale by synthetic means.
Although monophosphoryl lipid A and the AGPs have been described primarily for use in combination with antigens in vaccine formulations, their use as monotherapies, in the absence of antigen, for the prophyhlactic and/or therapeutic treatment of plant and animal diseases and conditions, such as infectious disease, autoimmunity and allergies, has not been previously reported.
The present invention, as a result of a growing understanding of certain mechanisms underlying the activities of monophosphoryl lipid A and AGP compounds, makes possible the novel therapeutic opportunities described herein.
In one aspect, the present invention provides methods for treating, ameliorating or substantially preventing a disease or condition in an animal by administering an effective amount of a compound having the formula:
OR*
R%0 Q
X Y
0 NH . 0
R'O
R?0
CH,
CHs ty and pharmaceutically acceptable salts thereof, wherein X is —O- or -NH-; R' and R? are each independently a (C,-Ca4)acyl group, including saturated, unsaturated and branched acyl groups; R3 is -H or —PO3;R!'R'?, wherein R!' and R'? are each independently —H or (Ci-Coalkyl; R* is -H, -CH; or -POsR“R!* wherein R" and R" are each independently selected from —H and (C,;-Cj)alkyl; and Y is a radical selected from the formulae:
; aly
OF bt GAY
R™ (CH /O NH $10 ls © and R%0
H3C
CHa (Ia) (Ib) wherein the subscripts n, m, p and q are each independently an integer of from 0 to 6;
R’ is a (C2-Cas)acyl group (including, as above, saturated, unsaturated and branched 5 acyl groups); R® and R’ are independently selected from H and CHj; R® and R’ are independently selected from H, OH, (C,-Cyalkoxy, -PO;H,, -OPOs;H,, -SO;H, -0SO;H, -NR'*R'S, _SR'®, -CN, -NO,, -CHO, -CO,R", -CONR"R'’, -PO;R"R", -
OPO;R"R'®, -SOsR'® and -OSOsR", wherein R"” and R'® are each independently selected from H and (C;-Cs)alkyl; R' is selected from H, CH, -POsH,, o-phosphonooxy(C,-Cas)alkyl, and e-carboxy(C;-Ca4)alkyl; and Z is —O- or —S-; with the proviso that when R} is —PO;R! 'R"2 R* is other than —-PO;R*R™.
In certain illustrative aspects of the invention, the above methods are employed in treating, ameliorating or substantially preventing infectious diseases, autoimmune diseases and allergies. :
The present invention, in other aspects, provides pharmaceutical compositions comprising one or more of the compounds described above in a suitable excipient, formulated and/or administered in the absence of exogenous antigen.
Figure 1 is a graph depicting the nonspecific protection of mice against lethal influenza challenge following or coincident with MonoPhosphoryl Lipid A (MPL) administration.
Figure 2 is a graph depicting clinical symptoms following intranasal administration of L-Seryl Aminoalkyl Glucosaminide Phosphates (AGPs) to mice.
Figure 3 is a graph depicting clinical symptoms following L-Seryl
Aminoalkyl Glucosaminide Phosphates (AGPs) monotherapy and influenza challenge.
Figures 4-6 are graphs depicting cytokine induction by RC522 as compared to MPL in overnight whole blood cultures from three human donors (donors
A-C, respectively).
Figure 7 are graphs depicting cytokine induction by RC522 as compared to MPL in short term whole blood cultures from donor A.
Figure 8 are graphs depicting cytokine induction by RC522 as compared to MPL in murine (Balb/c and C3H/HEJ) splenic cultures.
Figure 9 are graphs depicting cytokine induction by RC529 and RC552 as compared to MPL in human peripheral blood mononuclear cells (PBMC).
ILLUSTRATIVE PROPHYLACTIC AND THERAPEUTIC APPLICATIONS
The present invention broadly concerns prophylactic and therapeutic methods of treating certain diseases and other medical conditions by administration of an effective amount of one or more mono- or disaccharide compounds described herein or a pharmaceutical composition comprising one or more such compounds. While certain of the mono- and disaccharide compounds have been described for use as adjuvants in combination with exogenously administered antigens in vaccine formulations, and for use in certain other applications, the present invention provides novel therapeutic methods that employ the compounds preferably in monotherapeutic applications, i.e., in the absence of exogenously administered antigen.
Thus, in one aspect, the present invention provides methods for treating, ameliorating and/or substantially preventing infectious diseases in eukaryotic subjects, particularly in animals, preferably in humans. Given the importance of TLR-mediated signalling in the innate immune response to microbial challenge, the ability to stimulate such pathways selectively and with “mal toxicity represents a powerful approach for prophylactic and/or therapeutic treatment modalities against a wide range of infectious agents.
The methods described herein are applicable against essentially any type of infectious agent, including bacteria, viruses, parasites, and fungi. Illustratively, the invention is useful for the prophylactic and/or therapeutic treatment of bacterial infections by species from Pseudomonas, Escherichia, Klebsiella, Enterobacter,
Proteus, Serratia, Candida, Staphylococci, Streptococci, Chlamydia, Mycoplasma and numerous others. Illustrative viral conditions that may be treated in accordance with the invention include those caused, for example, by Influenza viruses, Adenoviruses, parainfluenza viruses, Rhinoviruses, respiratory syncytial viruses (RSVs), Herpes viruses, Cytomegaloviruses, Hepatitis viruses, e.g., Hepatitis B and C viruses, and others. Illustrative fungi include, for example, Aspergillis, Candida albicans,
Cryptococcus neoformans, Coccidioides immitus, and others.
In one illustrative embodiment, the invention provides methods for the treatment of subjects, particularly immunocompromised subjects, that have developed or are at risk for developing infections, such as nosocomial bacterial and viral infections. About 2 million of the 40 million individuals hospitalized every year develop nosocomial infection during their stay and about 1% of these, or about 400,000 patients, develop nosocomial pneumonia, more than 7000 of which die. This makes nosocomial pneumonia the leading cause of death in hospital-acquired infections.
Thus, this embodiment fills a significant need for effective prophylactic approaches in the treatment of nosocomial infections.
In a related embodiment, the present invention provides prophylactic treatments for immunocompromised patients, such as HIV-positive patients, who have developed or are at risk for developing pneumonia from either an opportunistic infection or from the reactivation of a suppressed or latent infection. In 1992, about 20,000 cases of Pneumocystis carinii infections in AIDS patients were reported in the
U.S. alone. Additionally, 60-70% of all AIDS patients get P.carinii at some time during their illness. Thus, the present invention in this embodiment provides effective prophylactic methods for this at-risk population.
In another related embodiment, the methods of the present invention are used for treating other patient populations that may be immunocompromised and/or at risk for developing infectious diseases, including, for example, patients with cystic fibrosis, chronic obstructive pulmonary disease and other immunocompromized and/or institutionalized patients.
In support of these and other embodiments of the invention, we have demonstrated that pre-challenge administration of an illustrative compound of the present invention in immunocompromised mice provides significant prophylactic protection against infection by Pneumocystis carinii. (See Example 1).
In another aspect of the invention, the mono- and disaccharide compounds described herein are employed in methods for treating, ameliorating or substantially preventing allergic disorders and conditions, such as sinusitis, chronic rhinosinusitus, asthma, atopic dermatitis and psoriasis. This approach is based at least in part on the ability of the mono- and disaccharide compounds to activate the production of cytokines from target cells that can compete with stereotypic allergic-type cytokine responses characterized by IL-4 production or hyperresponsiveness to IL-4 activity. Administration of certain of the mono- and disaccharide compounds disclosed herein results in IFN-gamma and IL-12 expression from antigen processing and presenting cells, as well as other cells, resulting in down regulation of cytokines associated with allergic responses such as IL-4, 5, 6, 10 and 13.
In another aspect of the invention, mono- and disaccharide compounds are employed in methods for treating autoimmune diseases and conditions. The mono- and disaccharide compounds for use in this embodiment will typically be selected from those capable of antagonizing, inhibiting or otherwise negatively modulating one or more Toll-like receptors, particularly Tir2 and/or Tlr4, such that an autoimmune
0 response associated with a given condition is ameliorated or substantially prevented.
Illustratively, the methods provided by this embodiment can be used in the treatment of conditions such as inflammatory bowel disease, rheumatoid arthritis, chronic arthritis, multiple sclerosis and psoriasis.
While not wishing to be bound by theory, it is believed that the efficacy of the prophylactic and therapeutic applications described above are based at least in part on the involvement of the mono- and disaccharide compounds in the modulation of
Toll-like receptor activity. In particular, Toll-like receptors Tlr2, Tir4, and others, are believed to be specifically activated, competitively inhibited or otherwise affected by the non-toxic LPS derivatives and mimetics disclosed herein. Accordingly, the methods of the invention provide a powerful and selective approach for modulating the innate immune response pathways in animals without giving rise to the toxicities often associated with the native bacterial components that normally stimulate those pathways
ILLUSTRATIVE MONO- AND DISACCHARIDE COMPOUNDS
Hlustrative mono- or disaccharide compounds employed in the above prophylactic and therapeutic applications comprise compounds having the formula:
OR*
R°0 > , X Y o NH 1 0)
RO
R?0
CH;
CH, @ and pharmaceutically acceptable salts thereof, wherein X is —O- or -NH-; R! and R? are each independently a (C,-Ca4)acyl group, including saturated, unsaturated and branched acyl groups; R? is -H or -PO;R''R'?, wherein R'! and R'? are each independently —H or (Ci-Cyalkyl; R* is -H, -CH; or -PO;RR™, wherein R!® and RY are each independently selected from —H and (C;-C4)alkyl; and Y is a radical selected from the formulae:
R’ 9 aie Fa
R™ (CHpp /O NH {g10
I i and R%0
HaC
CHs (Ia) (Ib) wherein the subscripts n, m, p and q are each independently an integer of from 0 to 6;
R’is a (C3-Cyg)acyl group (including, as above, saturated, unsaturated and branched acyl groups); R® and R7 are independently selected from H and CHj; R® and R® are independently selected from H, OH, (C,-Cyalkoxy, -POs;H,, -OPO;H,, -SOsH, -OSO;H, -NR"R'S, -SR", -CN, -NO,, -CHO, -CO,R", -CONR'’R'®, PO;R"*R"S, -
OPO;RR'®, -SOsR"S and -O0SO3sR", wherein R'® and R'® are each independently selected from H and (C;-Cs)alkyl; R!® is selected from H, CH;, -PO;H,, o-phosphonooxy(C,-Cyg)alkyl, and w-carboxy(C;-Cy4)alkyl; and Z is —O- or —S-; with the proviso that when R? is <POsR''R'?, R* is other than —-PO;R"R'*.
Additionally, when R® is -POs;H,, R* is H, R' is H, R' is »- tetradecanoyl, R? is n-octadecanoyl and R? is n-hexadecanoyl, then X is other than —O-.
In the general formula above, the configuration of the 3’ stereogenic centers to which the normal fatty acid acyl residues are attached is R or S, but preferably R. The stereochemistry of the carbon atoms to which R® and R are attached can be R or S. All stereoisomers, enantiomers, diastereomers and mixtures thereof are considered to be within the scope of the present invention.
In one group of preferred embodiments, Y has the formula: 2 OH nde
R® (CHa
I os
HaC (Ia).
Within this group of embodiments, the acyl groups R', R? and R® will be selected such that at least two of the groups are (C,-C¢)acyl. Further preferred are those embodiments in which the total number of carbon atoms in R!, R? and R® is from about 6 to about 22, more preferably about from about 12 to about 18. In other preferred embodiments, X is O and Z is O. The subscripts n, m, p and q are preferably integers of from 0 to 3, more preferably, 0 to 2. Of the remaining substituents, Rand R’ are preferably H. The present invention further contemplates those embodiments in which the preferred substituents are combined in one molecule.
In another group of embodiments, R', R? and R’ are selected from (C;p-
Cyp)acyl with the proviso that the total number of carbon atoms in R', R? and R’ is from about 44 to about 60. More preferably, the total number of carbon atoms in R', R? and
R’ is from about 46 to about 52. Still further preferred are those embodiments in which
X and Z are both —O-.
In another group of embodiments, Y has the formula: ~o
AY
HO
NH qR10 ~~ 0
CH; (Ib).
As with the preferred group of embodiments provided above, in this group the acyl groups R', R? and R’ will also be selected such that at least two of the groups are (C,-Cg)acyl. Further preferred are those embodiments in which the total number of carbon atoms in R', R? and R® is from about 6 to about 22, more preferably about from about 12 to about 18. In other preferred embodiments, X is O. Of the remaining substituents, R® is preferably phosphono (-PO3H,) and R* is preferably H.
The present invention further contemplates those embodiments in which various combinations of the preferred substituents are combined in one molecule.
In another group of embodiments, R!, R? and R° are selected from (Crz2-
Cz4)acyl with the proviso that the total number of carbon atoms in R!, R? and R? is from about 44 to about 60. More preferably, the total number of carbon atoms in R', R? and
R’ is from about 46 to about 52. Particularly preferred fatty acid groups for R', R? and
R® are normal C4, Cys and Cys fatty acid groups. Still further preferred are those embodiments in which X is —O-. Similar to the shorter acyl chain embodiments - provided above, R® is preferably phosphono (-PO3H,) and R* is preferably H.
In another preferred embodiments of the present invention, Y is a radical of formula (Ib), X is O, R? is phosphono, R* is H, and R, R? and R® are selected from (C12-Cas)acyl with the proviso that the total number of carbon atoms in R!, R? and R’ is from about 46 to about 52. Still further preferred are those compounds in which R? is (Cis-Cig)acyl.
The term “alkyl” by itself or as part of another substituent, means, unless otherwise stated, a straight or branched chain, or cyclic hydrocarbon radical, or combination thereof, which may be fully saturated, mono- or polyunsaturated and can include di- and multivalent radicals, having the number of carbon atoms designated (i.e, C;-Cjo means one to ten carbons). Examples of saturated hydrocarbon radicals include groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec- butyl, cyclohexyl, (cyclohexyl)methyl, cyclopropylmethyl, homologs and isomers of, for example, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like. An unsaturated alkyl group is one having one or more double bonds or triple bonds. Examples of unsaturated alkyl groups include vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4- pentadienyl, 3-(1,4-pentadienyl), ethynyl, 1- and 3-propynyl, 3-butynyl, and the higher homologs and isomers. Typically, an alkyl group will have from 1 to 24 carbon atoms.
A “lower alkyl” or is a shorter chain alkyl group, generally having eight or fewer carbon atoms.
The terms “alkoxy” “alkylamino” and “alkylthio” (or thioalkoxy) are used in their conventional sense, and refer to those alkyl groups attached to the remainder of the molecule via an oxygen atom, an amino group, or a sulfur atom, respectively.
The term “acyl” refers to a group derived from an organic acid by removal of the hydroxy group. Examples of acyl groups include acetyl, propionyl, dodecanoyl, tetradecanoyl, isobutyryl, and the like. Accordingly, the term “acyl” is meant to include a group otherwise defined as —~C(O)-alkyl.
Each of the above terms (e.g, “alkyl” “acyl”) are meant to include both substituted and unsubstituted forms of the indicated radical. Preferred substituents for each type of radical are provided below.
Substituents for the alkyl and acyl radicals can be a variety of groups selected from: -OR’, =O, =NR’, =N-OR’, -NR’R”, -SR’, -halogen, -SiR’R”R’”, -OC(O)R’, -C(O)R’, -COR’, -CONR’R”, -OC(O)NR’R”, -NR”C(O)R’, -NR’-C(O)NR"R””, -NR”C(O),R’, -NH-C(NH2)=NH, -NR’C(NH,)=NH, -NHC(NH2)=NR’, -S(O)R’, -S(OxR’, -S(O),NR’R”, -CN and -NO, in a number ranging from zero to (2m’+1), where m’ is the total number of carbon atoms in such radical. R’, R” and R™ each independently refer to hydrogen and unsubstituted (C;-
Cglalkyl. When R’ and R” are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 5-, 6-, or 7-membered ring. For example, -
NR’R” is meant to include I-pyrrolidinyl and 4-morpholinyl. From the above discussion of substituents, one of skill in the art will understand that the term “alkyl” is meant to include groups such as haloalkyl (e.g., -CF3 and -CH,CF;) and the like.
The term “pharmaceutically acceptable salts” is meant to include salts of the active compounds which are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein.
When compounds of the present invention contain relatively acidic functionalities, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent.
Examples of pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt.
When compounds of the present invention contain relatively basic functionalities, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent.
Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensuifuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, methanesulfonic, and the like.
Also included are salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, for example, Berge, S.M., et al, “Pharmaceutical Salts”, Journal of Pharmaceutical Science, 66, 1-19, 1977).
Certain specific compounds of the present invention contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts. -
The neutral forms of the compounds may be regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. The parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for the purposes of the present invention.
In addition to salt forms, the present invention provides compounds which are in a prodrug form. Prodrugs of the compounds described herein are those compounds that readily undergo chemical changes under physiological conditions to provide the compounds of the present invention. Additionally, prodrugs can be converted to the compounds of the present invention by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to the compounds of the present invention when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent.
Certain compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention. Certain compounds of the present invention may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present invention and are intended to be within the scope of the present invention.
Certain compounds of the present invention possess asymmetric carbon atoms (optical centers) or double bonds; the racemates, diastereomers, geometric isomers and individual isomers are all intended to be encompassed within the scope of the present invention.
The compounds of the present invention may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. For example, the compounds may be radiolabeled with radioactive isotopes, such as for example trittum (’H), iodine-125 (‘*I) or carbon-14 (*C). All
Isotopic variations of the compounds of the present invention, whether radioactive or not, are intended to be encompassed within the scope of the present invention.
The mono- and disaccharide compounds can be prepared by any suitable means, many of which have been described. For example, certain compounds useful in the present invention are described in co-pending applications Ser. Nos. 08/853,826, 09/439,839 (filed November 12, 1999) and in PCT/US98/09385, the disclosures of which are incorporated herein by reference in their entireties. Other compounds can be prepared in a manner similar to that described for RC-552 (1.34) in U.S. Patent No. 6,013,640. Still other compounds can be prepared using methods outlined in Johnson, et al., J. Med. Chem. 42:4640-4649 (1999), Johnson, et al., Bioorg. Med. Chem. Lett. 9:2273-2278 (1999), and PCT/US98/50399. Still other compounds can be prepared according to, for example, U.S. Patent Nos. 4,436,727; 4,877,611; 4,866,034; 4,912,094; and 4,987,237. In general, the synthetic methods described in the above- noted references and other synthetic methods otherwise familiar in the art are broadly applicable to the preparation these compounds. For example, in making compounds having different acyl groups and substitutions, one of skill in the art will appreciate that the convergent methods described therein can be modified to use alternate acylating agents, or can be initiated with commercially available materials having appropriate acyl groups attached.
ILLUSTRATIVE PHARMACEUTICAL COMPOSITIONS AND THEIR DELIVERY
In another embodiment, the present invention concerns pharmaceutical compositions comprising one or more of thc mono- and disaccharide compounds disclosed herein in pharmaceutically-acceptable carriers/excipients for administration to a cell, tissue, animal or plant, either alone, or in combination with one or more other modalities of therapy. In a preferred embodiment, the pharmaceutical compositions are * U.S. patent 08/853,826 . %% [.S. pateat 6,303,347
Amended Sheet — 2004-03-30 formulated in the absence of exogenous antigen, ie., are used in monotherapeutic applications. For many such embodiments, the pharmaceutical compositions of the invention will comprise one or more of the monosaccharide compounds described . herein.
Illustrative carriers for use in formulating the pharmaceutical compositions include, for example, oil-in-water or water-in-oil emulsions, aqueous compositions with or without inclusion of organic co-solvents suitable for intravenous (IV) use, liposomes or surfactant-containing vesicles, microspheres, microbeads and microsomes, powders, tablets, capsules, suppositories, aqueous suspensions, aerosols, and other carriers apparent to one of ordinary skill in the art.
In certain embodiments, the pharmaceutical compositions will comprise one or more buffers (e.g, neutral buffered saline or phosphate buffered saline), carbohydrates (e.g., glucose, mannose, sucrose or dextrans), mannitol, proteins, polypeptides or amino acids such as glycine, antioxidants, bacteriostats, chelating agents such as EDTA or glutathione, adjuvants (e.g., aluminum hydroxide), solutes that render the formulation isotonic, hypotonic or weakly hypertonic with the blood of a * recipient, suspending agents, thickening agents and/or preservatives.
For certain applications, aqueous formulations will be preferred, particularly those comprising an effective amount of one or more surfactants. For example, the composition can be in the form of a micellar dispersion comprising at least one suitable surfactant, e.g., a phospholipid surfactant. Illustrative examples of phospholipids include diacyl phosphatidyl glycerols, such as dimyristoyl phosphatidyl glycerol (DPMG), dipalmitoyl phosphatidyl glycerol (DPPG), and distearoyl phosphatidyl glycerol (DSPG), diacyl phosphatidyl cholines, such as dimyristoyl phosphatidylcholine (DPMC), dipalmitoyl phosphatidylcholine (DPPC), and distearoyl phosphatidylcholine (DSPC); diacyl phosphatidic acids, such as dimyristoyl phosphatidic acid (DPMA), dipalmitoyl phosphatidic acid (DPPA), and distearoyl } phosphatidic acid (DSPA); and diacyl phosphatidyl ethanolamines such as dimyristoyl phosphatidyl ethanolamine (DPME), dipalmitoyl phosphatidy! ethanolamine (DPPE) and distearoyl phosphatidyl ethanolamine (DSPE). Typically, a surfactant:mono-
/disaccharide molar ratio in an aqueous formulation will be from about 10:1 to about 1:10, more typically from about 5:1 to about 1:5, however any effective amount of surfactant may be used in an aqueous formulation to best suit the specific objectives of interest.
The compounds and pharmaceutical compositions of the invention can be formulated for essentially any route of administration, e.g., injection, inhalation by oral or intranasal routes, rectal , vaginal or intratracheal instillation, ingestion, or transdermal or transmucosal routes, and the like. In this way, the therapeutic effects attainable by the methods and compositions of the invention can be, for example, systemic, local, tissue-specific, etc., depending of the specific needs of a given . application of the invention. lustrative formulations can be prepared and administered parenterally, i.e, intraperitoneally, subcutaneously, intramuscularly or intravenously. One : illustrative example of a carrier for intravenous use includes a mixture of 10% USP ethanol, 40% USP propylene glycol or polyethylene glycol 600 and the balance USP
Water for Injection (WFI). Other illustrative carriers include 10% USP ethanol and
USP WFI; 0.01-0.1% triethanolamine in USP WFL, or 0.01-0.2% dipalmitoyl diphosphatidylcholine in USP WFI; and 1-10% squalene or parenteral vegetable oil-in- water emulsion. Pharmaceutically acceptable parenteral solvents will generally be selected such that they provide a solution or dispersion which may be filtered through a 0.22 micron filter without removing the active ingredient. [Hustrative examples of carriers for subcutaneous or intramuscular use include phosphate buffered saline (PBS) solution, 5% dextrose in WFI and 0.01-0.1% triethanolamine in 5% dextrose or 0.9% sodium chloride in USP WFI, oral to2 or 1 to 4 mixture of 10% USP ethanol, 40% propylene glycol and the balance an acceptable isotonic solution such as 5% dextrose or 0.9% sodium chloride; or 0.01-0.2% dipalmitoyl diphosphatidylcholine in USP WFI and 1 to 10% squalene or parenteral vegetable oil-in-water emulsions.
Examples of carriers for administration via mucosal surfaces depend upon the particular route, e.g., oral, sublingual, intranasal, etc. When administered orally, illustrative examples include pharmaceutical grades of mannitol, starch, lactose, . magnesium stearate, sodium saccharide, cellulose, magnesium carbonate and the like, with mannitol being preferred. When administered intranasally, illustrative examples include polyethylene glycol, phospholipids, glycols and glycolipids, sucrose, and/or methylcellulose, powder suspensions with or without bulking agents such as lactose and preservatives such as benzalkonium chloride, EDTA. In a particularly illustrative embodiment, the phospholipid 1,2 dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) is used as an isotonic aqueous carrier at about 0.01-0.2% for intranasal administration of the compound of the subject invention at a concentration of about 0.1 to 3.0 mg/ml.
When administered by inhalation, illustrative carriers include polyethylene glycol or glycols, DPPC, methylcellulose, powdered dispersing agents, and preservatives, with polyethylene glycols and DPPC being preferred. In many instances, it will be preferred that the mono- or disaccharide compounds be in a nebulized form when administration by inhalation. Illustratively, delivery may be by use of a single-use delivery device, a mist nebulizer, a breath-activated powder inhaler, an aerosol metered-dose inhaler (MDI) or any other of the numerous nebulizer delivery devices available in the art. Additionally, mist tents or direct administration through endotracheal tubes may also be used. Delivery via an intratracheal or nasopharyngeal mode will be efficacious for certain indications.
One skilled in this art will recognize that the above description is illustrative rather than exhaustive. Indeed, many additional formulations techniques and pharmaceutically-acceptable excipients and carrier solutions are well-known to those skilled in the art, as is the development of suitable dosing and treatment regimens for using the particular compositions described herein in a variety of treatment regimens.
The compounds can be evaluated in a variety of assay formats to identify and select those having the characteristics best suited for a given application of the invention. For example, animal models can be used for identifying and evaluating cytokine release profiles into systemic circulation following administration of a mono- and/or disaccharide compound. In addition, various in vitro and in vivo models exist for examining changes in one or more aspects of an immune response to different antigenic components in order to identify compounds best suited for eliciting a specific immune response of interest. For example, a compound can be contacted with target cells, such as macrophages, dendritic cells or Langerhans cells in vitro, and elaborated © 5 cytokines can be measured. In addition, gene expression arrays can be used to identify specific pathways activated or inhibited by a particular mono- or disaccharide of interest.
It will be understood that, if desired, the compounds disclosed herein may be administered in combination with other therapeutic modalities, such as antimicrobial, antiviral and antifungal compounds or therapies, various DNA-based therapeutics, RNA-based therapeutics, polypeptide-based therapeutics. and/or with other immunoeffectors. In fact, essentially any other component may also be included, given that the additional component(s) do not cause a significant adverse effect upon contact with the target cells or host tissues. The compositions may thus be delivered along with various other agents as required or desired for the specific embodiment(s) of the invention being implemented.
Illustratively, the pharmaceutical compositions of the invention can include, or be used in conjunction with, DNA encoding one or more therapeutic proteins, antisense RNAs, ribozymes or the like. The DNA may be present within any of a variety of delivery systems known to those of ordinary skill in the art, including nucleic acid expression systems, bacteria and viral expression systems. Numerous gene delivery techniques are well known in the art, such as those described by Rolland, Crit.
Rev. Therap. Drug Carrier Systems 15:143-198, 1998, and references cited therein.
Appropriate nucleic acid expression systems contain the necessary DNA sequences for expression in the patient (such as a suitable promoter and terminating signal). In a preferred embodiment, the DNA may be introduced using a viral expression system (e.g., vaccinia or other pox virus, retrovirus, or adenovirus), which may involve the use of a non-pathogenic (defective), replication competent virus. Suitable systems are disclosed, for example, in Fisher-Hoch et al., Proc. Natl. Acad. Sci. USA 86:317-321, 1989; Flexner et al., Ann. N.Y. Acad. Sci. 569:86-103, 1989; Flexner et al., Vaccine
8:17-21, 1990; U.S. Patent Nos. 4,603,112, 4,769,330, and 5,017,487; WO 89/01973;
U.S. Patent No. 4,777,127; GB 2,200,651; EP 0,345,242; WO 91/02805; Berkner,
Biotechniques 6:616-627, 1988; Rosenfeld et al., Science 252:431-434, 1991; Kolls et al., Proc. Natl. Acad. Sci. USA 91:215-219, 1994; Kass-Eisler et al., Proc. Natl. Acad.
Sci. USA 90:11498-11502, 1993; Guzman et al., Circulation 88:2838-2848, 1993; and
Guzman et al., Cir. Res. 73:1202-1207, 1993. Techniques for incorporating DNA into such expression systems are well known to those of ordinary skill in the art.
The DNA may also be "naked," as described, for example, in Ulmer et al., Science 259:1745-1749, 1993 and reviewed by Cohen, Science 259:1691-1692, 1993. The uptake of naked DNA may be increased by coating the DNA onto biodegradable beads, which are efficiently transported into the cells. It will be apparent that a pharmaceutical composition of the invention may comprise both a polynucleotide and a protein component.
Any of a variety of additional immunostimulants may be included in the compositions of this invention. For example, cytokines, such as GM-CSF, interferons or interleukins to further modulate an immune response of interest. For example, in certain embodiments, additional components may be included in the compositions to further enhance the induction of high levels of Thl-type cytokines (e.g., IFN-y, TNFa,
IL-2 and IL-12). Alternatively, or in addition, high levels of Th2-type cytokines (e.g.,
IL-4, IL-5, IL-6 and IL-10) may be desired for certain therapeutic applications. The levels of these cytokines may be readily assessed using standard assays. For a review of the families of cytokines, see Mosmann and Coffman, Ann. Rev. Immunol. 7:145- 173, 1989.
Illustrative compositions for use in induction of Thl-type cytokines include, for example, a combination of CpG-containing oligonucleotides (in which the
CpG dinucleotide is unmethylated) as described, for example, in WO 96/02555, WO 99/33488 and U.S. Patent Nos. 6,008,200 and 5,856,462. Immunostimuiatory DNA sequences are also described, for example, by Sato et al., Science 273:352, 1996. Other suitable immunostimulants comprise saponins, such as QS21 (Aquila
Biopharmaceuticals Inc., Framingham, MA), and related saponin deriviatives and mimetics thereof.
Other illustrative immunostimulants that can be used in conjunction with the present invention include Montanide ISA 720 (Seppic, France), SAF (Chiron,
California, United States), ISCOMS (CSL), MF-59 (Chiron), the SBAS series of adjuvants (e.g., SBAS-2 or SBAS-4, available from SmithKline Beecham, Rixensart,
Belgium), and Enhanzyn™ immunostimulant (Corixa, Hamilton, MT). Polyoxyethylene ether immunostimulants, are described in WO 99/52549A1.
GENERAL DEFINITIONS:
As used herein, "an effective amount” is that amount which shows a response over and above the vehicle or negative controls. As discussed above, the precise dosage of the compound of the subject invention to be administered to a patient will depend the route of administration, the pharmaceutical composition, and the patient.
The phrase "pharmaceutically-acceptable” refers to molecular entities and compositions that do not produce an allergic or similar untoward reaction when administered to a human.
As used herein, "carrier" or “excipient” includes any and all solvents, dispersion media, vehicles, coatings, diluents, antibacterial and antifungal agents, isotonic and absorption delaying agents, buffers, carrier solutions, suspensions, colloids, and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated.
EXAMPLE 1
PROTECTION AGAINST P. CARINII INFECTION BY PROPHYLACTIC ADMINISTRATION OF
MONOPHOSPHORYL LIPID A
Mice were pretreated with L3T4 anti-CD4 antibody for a minimum of 2 weeks (2 injections/week, 0.2 mg/injection) or until the peripheral CD4 count was reduced by at least about 50%.
An aqueous formulation was prepared containing 1 mg/ml 3-O- deacylated monophosphoryl lipid A and 108 pg/ml of the surfactant DPPC in water.
The formulation was administered intratracheally via a small cannula at -24 hours and then twice a week for the remainder of the study. The concentrations administered are indicated below in Table 1. One million P. carinii were inoculated trans-tracheally at day 0. Twice-weekly treatments were continued for 7 weeks, lungs were removed and impression smears made. Slides were stained with Giemsa and silver and scored for the presence of P. carinni as follows.
Score 5 >100/1000x field 4 10-100/field 3 1-10/field 2 1-10/10 fields 1 1-10/50 fields 0 0/50 fields
The results of these experiments are summarized below in Table 1:
TABLE 1
Giemsa Silver
Placebo group 3.30.7 2.5£04 25 pg/kg 3.440.5 3.3%0.1 100 pg/kg 2.70.5 3.2+0.1 250 pg/kg 1.8+0.8 1.6+0.2
This study was repeated and the following results were obtained (Table 5S 2)
TABLE 2
Giemsa
Placebo group 3.3+£0.2
Untreated Control 3.1+0.3 100 pg/kg 1.30.3 200 pg/kg 1.00.3
These results demonstrate that pulmonary delivery of monophosphoryl lipid A promotes nonspecific resistance to infection by Pneumocystis carinii in immunocompromised mice. Inhalation of monophosphoryl lipid A led to activation of the local (and distal) innate immune responses resulting in enhanced nonspecific protection. Monophosphoryl lipid A mediated this protection primarily through activation of antigen presenting cells leading to increased phagocytic activity and the release of immuno-stimulatory cytokines. FACS analysis of cell lavaged from the lungs displayed markers for activated neutrophils but was unremarkable for an influx of leukocytes characteristic of a massive inflammatory response (ARDS). Analysis of spleen cells showed negative expression of CD1lb or CD69, suggesting that the monophosphoryl lipid A formulations and the effects in this application were not systemic but were confined to the lung.
EXAMPLE 2 oo
PROTECTION AGAINST LETHAL INFLUENZA CHALLENGEBY
PROPHYLACTIC ADMINISTRATION OF MONOPHOSPHORYL LIPID A
A dose of 20 pg MonoPhosphoryl Lipid A (MPL) was given to groups of female BALB/c mice by intranasal (i.n.) administration either 2 days prior to or the day of lethal influenza challenge. All mice were challenged with approximately 2
LD50 infectious influenza A/HK/68 administered i.n. Mortality was monitored for 21 days following influenza challenge. The results of these experiments is presented in
Figure 1. These data demonstrate that intranasal delivery of monophosphoryl lipid A promotes nonspecific resistance to infection by lethal influenza challenge in mice.
EXAMPLE 3 :
CLINICAL SYMPTOMS FOLLOWING INTRANASAL ADMINISTRATION OF L-SERYL
AMINALKYL GLUCOSAMINIDE PHOSPHATES (AGPS)
A series of L-Seryl Aminoalkyl Glucosaminide Phosphate compounds (AGPs) was prepared as described in U.S. Patent No. 6,113,918, issued September 3, 2000, and in U.S. Patent Application No. 09/439,839 filed November 12, 1999, each of which is incorporated herein by reference in its entirety.
A dose of 20 pg of L-Seryl AGPs (RC-526, RC-554, RC-555, RC-537,
RC-527, RC-538, RC-560, RC-512 and vehicle only) was given to groups of female
BALB/c mice by intranasal (i.n.) administration. During the initial 4 days following
AGP administration, the mice were monitored for three subjective indicators of disease (i.e. disease index) including observing ruffled fur, hunched posture and labored breathing. The results of these experiments is presented in Figure 2. These data indicated that i.n. administration of the RC-537, RC-527, RC-538 and RC-560 induce some toxicity in mice at the given dose of 20 pg. # U.S. patent 6,303,347
Amended Sheet — 2004-03-30
EXAMPLE 4
CLINICAL SYMPTOMS FOLLOWING INTRANASAL ADMINISTRATION OF L-SERYL - AMINALKYL GLUCOSAMINIDE PHOSPHATES (A GPS) AND INFLUENZA CHALLENGE
A dose of 20 pg L-Seryl AGPs (RC-526, RC-554, RC-555, RC-537, RC- 527, RC-538, RC-560, RC-512 and vehicle only) was given to groups of female
BALB/c mice by intranasal (i.n.) administration 2 days prior to or the day of lethal influenza challenge. All mice were challenged with approximately 2 LD50 infectious influenza A/HK/68 administered i.n.. The disease index (ruffled fur, hunched posture and labored breathing) was monitored during days 4-19 following influenza challenge.
Weight loss and mortality were monitored for 21 days following influenza challenge.
The results of these experiments are presented in Figure 3. :
These data demonstrated the efficacy of AGP compounds RC-538,
RC560 and RC-512 in providing substantial protection against influenza challenge.
EXAMPLE 5
CoMPARISON OF RC552 AND MPL USING HUMAN WHOLE BLOOD CULTURES AND
MOUSE SPLENIC CULTURES
This Example discloses cytokine induction by the synthetic lipid A compound RC552 as compared to the modified natural substance monophosphoryl lipid
A (MPL) using human whole blood cultures and mouse splenocyte culture.
Lipid A compounds were tested by reconstitution in 0.2% triethanolamine in sterile water for irrigation, incubated at 56°C and sonicated for 2x 10 minutes at 37°C. LPS O55B5 (Sigma-Aldrich; St Louis, MO) was diluted into PBS.
Compounds were added to 450 pl of human whole blood and incubated with agitation for 5 to 24 hours. Three donors were selected (Figures 4-6, donors A-C, respectively). Supernatants were collected by centrifugation and diluted to 1/2 with an equal volume of PBS. (This dilution was not considered a dilution factor for cytokine calculations). Cytokine elaboration was measured by ELISA (R&D Systems;
Minneapolis, MN) using the required volume of supernatant at full strength or diluted as much as ten fold.
BALB/c, DBA/2 and C3H/HEJ mice were purchased from The Jackson
Laboratory (Bar Harbor, ME). Spleens were taken from the mice between 2PM and 3
PM, and separate single cell suspensions were obtained for each mouse strain. Red blood cells were lysed using Tris-ammonium chloride solution (Sigma-Aldrich), cells were washed and counted using Trypan Blue (Sigma-Aldrich) exclusion. One million splenocytes were cultured per well in 1.0 mL of culture medium. Splenic culture medium (SCM) was designed for 5 day or longer cultures of mouse splenocytes and consisted of RPMI 1640 (Sigma-Aldrich) supplemented to 5% with fetal bovine serum (HyClone; Logan, UT), 100 ug/mL Gentamicin (Sigma-Aldrich), 250 ng/mL amphothericin (InVitrogen Life Technologies; Carlsbad, California), 1x ITS (bovine insulin 500 ng/mL, human transferring 500 ng/mLg , sodium selenite 250 ng/mL,
Sigma), beta-mercaptoethanol 43nM (Sigma-Aldrich) purivic acid 1 mM (Sigma-
Aldrich), HEPES 10 mM (Sigma-Aldrich). Data from these experiments is presented herein as Figure 8.
Using human whole blood cultures, four cytokines were measured: IL- 10, MIP-1 beta, TNF alpha, and IL-8. Two donors were tested once and one donor was tested twice. It is noteworthy that the donor who was tested twice had very high background TNF alpha at one test, but very low background TNF alpha one month later. Significant, however, is the time span of culture. High background TNF alpha was obtained with a 5.5 hour culture, and low background TNF alpha was obtained with an overnight, about 24 hour, culture. Nonetheless, even the 5.5 hour-low background culture was higher (about 600 pg/ml) than obtained in some previous cultures (518.2 pg/ml in a5 hr test; 417 pg/ml in a 4 hr test; zero pg/ml 4 hr, low responder).
RC552 was similar to MPL for elaboration of TNF alpha in two of three 24 hours cultures, and one 5.5 hour culture. IL-8 induction, however, by RC552 was different than that for MPL in three of three cases. IL-8 induction by RC552 was lessened for two overnight cultures compared to MPL, but greater than MPL in one overnight culture.
For overnight cultures, IL-10 induction by RC552 was less than that for
MPL. MIP-1 beta induction was lessened in one of 3 cases of overnight culture.
BALB/c responses and C3H/HEJ responses were compared for MPL and
RC552. C3H/HEJ mice are genetic hyporesponders to LPS due to a mutation in toll- receptor 4. In these cultures, an oligonucleotide stimulant was used as a positive control for C3H/HEJ cultures. This oligonucleotide induced large amounts of IL-6 in
BALB/c mice (1000 pg/mL) and in C3H/HEJ mice (488.5 pg/mL). Similarly, MIP-1 beta was induced in BALB/c and C3H/HEJ cultures (589 pg/mL and 554 pg/mL), as was IL-10 (342 pg/mL and 609 pg/mL), and TNF alpha (204 pg/mL and 30 pg/mL) in response to 10 ug/mL MPL or RC552, respectively.
Neither MPL nor RC552 induced a cytokine response using C3H/HEJ splenocytes. In BALB/c splenocyte cultures, however, IL-10, MIP-1 beta, TNF alpha and IL-6 were induced. RC552 induced less MIP-1 beta, TNF alpha and IL-6 than did
MPL at the same concentrations. RC552 induced very little IL-10 (10.4 to 11.6 pg/mL) compared to MPL (1144.1 to 176.6 pg/mL).
When tested in a solution of 0.2% triethanolamine, RC552 has a similar but not identical pro-inflammatory profile for TNF alpha induction as does MPL in two of three overnight cultures and one short-term culture of human whole blood. See,
Figures 4-6 (overnight cultures for donors A-C, respectively) and Figure 7 (short-term culture for donor A). In addition, MIP-1 beta induction by RC552 was similar in two of three overnight cultures. Lessened IL-10 was induced by RC552 than MPL in one overnight culture. IL-8 induction was different than that for MPL in all cases tested.
Using receptor deficient mice, it was clear that RC552 signals via toll- like receptor 4. Using BALB/c mice that are lipid A responsive, RC552 induced a lessened cytokine profile at the concentrations tested. Interestingly, the concentrations tested were at the high end of a dose response relationship, and RC552 induced slightly greater MIP-1 beta and TNF alpha at the lower concentration (10 pg/mL) than at the higher concentration (20 pg/mL) tested.
By comparing the human and mouse cytokine profiles, synthetic lipid A compound RC552 lessened capacity for IL-10 induction in 2 day mouse splenocyte cultures and in 1 of 3 human blood cultures overnight, when tested at high concentrations of stimulant. In general, less TNF alpha was induced in overnight human blood cultures by RC552 than MPL. About equal TNF alpha levels were induced in short term (5.5 hour) cultures of human blood by RC552 compared to MPL.
Microarray data using RNA obtained from human macrophage stimulated with RC552 and MPL indicated early (1 hour) TNF alpha RNA for both compounds, and no late
TNF alpha RNA for both compounds. RC552, however, induced very little 6 hour TNF alpha as opposed to MPL which had measurable 6 hour RNA.
EXAMPLE 6 0 RC529 STIMULATORY CAPABILITIES COMPARED TO MPL AND RC552
This Example demonstrates that RC529 has superior immune stimulatory capabilities as sompared to MPL when assessed by IL-6, IL-10 and MIP-
Ibeta elaboration from human peripheral blood mononuclear cells (PBMC). In contrast, IL-8 elaboration was similar to that of MPL.
PBMC were stored frozen until used. PBMC donor designation was
AD112. PBMC at a density of 6.26 x 10° were plated per well in a 48 well plate in 1.0 ml of medium. Medium consisted of RPMI-1640 plus sodium bicarbonate, 10% fetal bovine serum, 4 mM glutamine, 100 ug/ml gentamicin and 10 mM HEPES. PBMC were cultured for 22 hours at 37°C in a carbon dioxide incubator. Supernatants were harvested and tested by ELISA (R&D Systems) for IL-6, IL-8, IL-10 and MIP-1 beta concentration. Cytokine concentration in supernatants was compared to supernatants obtained from unstimulated PBMC cultured identically.
At the doses tested, RC529 did not achieve dose-responsiveness at the lowest dose for IL-6 or IL-8. Compared to MPL, RC529 induced more IL-6, IL-10 and
MIP-1 beta than did MPL. A disaccharide compound, RC552 was generally intermediate in stimulatory capability on a mass basis. See, Figure 9. These data show that RC529 is a strong inducer of IL-6, IL-10 and MIP-1 beta from frozen human
PBMC.
All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.
Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.
Claims (32)
1. Use of one or more compounds having the formula: OR? R%0 Q X Y 0 NH 1 0 RO R?O CHa CH, and pharmaceutically acceptable salts thereof, wherein X'is a member selected from the group consisting of ~O- and -NH-; R' and R? are each members independently selected from the group consisting of (C,-Caq)acyl; R® is a member selected from the group consisting of -H and — PO;R''R™, wherein R'" and R'? are each members independently selected from the group consisting of =H and (C,-Cy)alkyl; R* is a member selected from the group consisting of —H, -CH; and -PO;RPR™, wherein R'® and R'* are each members independently selected from the group consisting of —H and (C,-Cy)alkyl; and Amended Sheet — 2004-03-30
Y is a radical selected from the group consisting of rR’ 9 R™ (CH /O NH R10 Ie i 0 and R50 HaC CHa wherein the subscripts n, m, p and q are each independently an integer of from 0 to 6;
R’ is (C3-Caq)acyl;
R® and R’ are members independently selected from the group consisting of H and CH;
R® and R® are members independently selected from the group consisting of H, OH, (C)-Cy)alkoxy, -PO3Ha, -OPO3Ha, -SO;H, -0SO;H, -NRR!S, -SR'S, -CN, -NO,, -CHO, -CO,R”, -CONR"R'S, -PO;R"R', -OPO;R"R'®, -SOsR" and - OSO0;R' wherein R'° and R' are each members independently selected from the group consisting of H and (C-Cy)alkyl; h
R'is a member selected from the group consisting of H, CHj, -PO3H,, o-phosphonooxy(Co-Canalkyl, and o-carboxy(Cy-Can)alkyl: and Z1s-0-or -S-; with the proviso that when R3is —PO3R''R'2, R* is other than ~PO;RPRY and with the further proviso that when R? is ~POsH,, RY is H, R'is H, R'is n-tetradecanoyl,, R?is n-
Amended Sheet — 2004-03-30 octadecanoyl and R® is n-hexadecanoyl, then X is other than —O-, in the manufacture of a medicament for use in a method for ameliorating or substantially preventing an infectious disease, autoimmune disease or allergic condition in a subject comprising contacting the subject with an effective amount of the compound in the absence of exogenous antigen.
2. Use in accordance with claim 1, wherein the infectious disease is caused by a bacteria selected from the group consisting of Pseudomonas, Escherichia, Klebsiella, Enterobacter, Proteus, Serratia, Candida and Staphylococcus.
3. Use in accordance with claim 1, wherein the infectious disease or condition is pneumonia.
4. Use in accordance with claim 3, wherein said pneumonia is nosocomial pneumonia.
5. Use in accordance with claim 3, wherein said pneumonia is in an HIV-positive patient.
6. Use in accordance with claim 1, wherein said infectious disease or condition is a chronic infection.
7. Use in accordance with claim 6, wherein said chronic infection comprises chronic hepatitis, human papillomavirus, oral or vaginal candidiasis, periodontal disease or chronic rhinosinusitis due to fungal colonization.
8. Use in accordance with claim 1, wherein said allergic condition is selected from the group consisting of asthma, atopic dermatitis, seasonal allergic disorder and chronic rhinosinusitis.
9. Use in accordance with claim 1, wherein said autoimmune disease is selected from the group consisting of inflammatory bowel disease, rheumatoid arthritis, chronic arthritis, multiple sclerosis and psoriasis. Amended Sheet — 2004-03-30
10. Use in accordance with claim 1, wherein said compound is administered to said subject by a route selected from the group consisting of parenteral, oral, intravenous, infusion, intranasal, inhalation, transdermal and transmucosal.
11. Use in accordance with claim 1, wherein at least two of said R!, R? and R’ are selected from the group consisting of (C,-Cg)acyl.
12. Use in accordance with claim 1, wherein two of said R!, rR? and R® are selected from the group consisting of (C2-Ce)acyl and the total number of carbon atoms in RY R? and R? is from about 6 to about 22.
13. Use in accordance with claim 1, wherein two of said rR, R? and R® are selected from the group consisting of (C2-Cg)acyl and the total number of carbon atoms in R', R? and R® is from about 12 to about 18.
14. Use in accordance with claim 1, wherein X and Z are both
-O-.
15. Use in accordance with claim 1, wherein R!, R? and R® are each independently selected from the group consisting of (C,2-Ca4)acyl with the proviso that the total number of carbon atoms in R', R? and R’ is from about 44 to about 60.
16. Use in accordance with claim 15, wherein said total number of carbon atoms is from about 46 to about 52.
17. Use in accordance with claim15, wherein X and Z are both
-O-. Amended Sheet — 2004-03-30
18. Use of one or more compounds having the formula: OR* R30 N 0] Ay 0 NH 1 0) RO R%0 CH CH, and pharmaceutically acceptable salts thereof, wherein X 1s a member selected from the group consisting of —O- and -NH-; R' and R? are each members independently selected from the group consisting of (Cy-Cag)acyl; R’ is a member selected from the group consisting of -H and — PO;R''R'?, wherein R'' and R'? are each members independently selected from the group consisting of =H and (C;-Cy)alkyl;
R* is a member selected from the group consisting of —H, -CH; and -PO;R"’R™, wherein R'? and R'" are each members independently selected from the group consisting of =H and (C;-Cs)alkyl; and
Amended Sheet — 2004-03-30
Y is a radical selected from the group consisting of 7 ~o tdi FA R™ (CHy)p Oo | NH Hr10 : I 0 and R50 HaC CHa wherein the subscripts n, m, p and q are each independently an integer of : from 0 to 6; R’ is (Co-Caq)acyl; R® and R’ are members independently selected from the group consisting of H and CHj; R® and R® are members independently selected from the group consisting of H, OH, (C,-Cqalkoxy, -PO3H,, -OPO3H,, -SO;H, -OSOsH, -NR"R'¢, -SR'®, -CN, NO,, -CHO, -CO;R", -CONR"R'®, -PO,R"R'S, -OPO;R"R'®, -SO;R" and - 0SO5R'® wherein R*® and R'® are each members independently selected from the group consisting of H and (C;-Cy)alkyl; R%isa member selected from the group consisting of H, CHa, -PO3H,, o-phosphonooxy(Cy-Ca4)alkyl, and w-carboxy(C,-Caq)alkyl; and Z is —=0- or -S-; with the proviso that when R? is -PO;R''R'2, R! is other than —PO,R"RM, and with the further proviso that when R? is -POsH,, RY is H, R'%isH, R'is n-tetradecanoyl, R? is n- Amended Sheet — 2004-03-30
37A octadecanoyl and R’ is n-hexadecanoyl, then X is other than —O-, in the manufacture of a medicament for use in a method for the prophylactic treatment of a bacterial or viral infection in a subject comprising contacting the subject with an effective amount of the compound in the absence of exogenous antigen. : Amended Sheet — 2004-03-30
19. Use in accordance with claim 18, wherein said infection is a nosocomial infection.
20. Use In accordance with claim 19, wherein said nosocomial infection is a pneumonia.
21. Use 1n accordance with claim 18, wherein said infection is in an HIV-positive patient.
22. Use in accordance with claim 21, wherein the infection in said HIV-positive patient is pneumonia.
23. Use in accordance with claim 22, wherein said infection is caused by P. carinii.
24. A pharmaceutical composition formulated and administered in the absence of exogenous antigen comprising one or more compounds having the formula: OR* RO 0 a X Y O NH 0 R'O : R20 CH, ( CH, and pharmaceutically acceptable salts thereof, wherein Amended Sheet — 2004-03-30
X is a member selected from the group consisting of —O- and —-NH-; R' and R? are each members independently selected from the group consisting of (C,-Caq)acyl;
R? is a member selected from the group consisting of -H and - POsR'"R', wherein R" and R'? are each members independently selected from the group consisting of —H and (C,-Cy)alkyl;
R* is a member selected from the group consisting of -H, -CH; and -PO;RPR™, wherein R'? and R™ are each members independently selected from the group consisting of —H and (C;-Cy)alkyl; and Y is a radical selected from the group consisting of R’ a R® (CHypp /=O NH HR10 I! 0 and R®O H4C oo CH, wherein the subscripts n, m, p and q are each independently an integer of from 0 to 6; oo R> is (Cp-Cayacyl; R® and R” are members independently selected from the group consisting of H and CHs; R® and R® are members independently selected from the group consisting of H, OH, (C,-Cyalkoxy, -PO3Ha, -OPO3,, -SO3H, -0SO;H, -NR'R'¢, -SR", -CN, NO,, -CHO, -CO;RY, -CONR"R', -POR"R', -OPO;R"R'®, -SO;R" and - 0SO;R'® wherein R'® and R'® are each members independently selected from the group consisting of IT and (C,-Cy)alkyl; Amended Sheet — 2004-03-30
R'% is a member selected from the group consisting of H, CHj, -POsHa, o-phosphonooxy(C,-Cas)alkyl, and @-carboxy(C,-Cy4)alkyl; and Z is -0O- or —S-; with the proviso that when R3 is -PO;R'R! 2 R*is other than ~PO;RPR™ and with the further proviso that when R? is -POsH,, R? is H, R'% is H, R' is n-tetradecanoyl, R* is n- octadecanoyl and R® is n-hexadecanoyl, then X is other than —O-.
25. A pharmaceutical composition in accordance with claim 24, further comprising one or more surfactants. ©
26. A pharmaceutical composition in accordance with claim 25, wherein said one or more surfactants is selected from the group consisting of dimyristoyl phosphatidyl glycerol (DPMG), dipalmitoyl phosphatidyl glycerol (DPPG), distearoyl phosphatidyl glycerol (DSPG), dimyristoyl phosphatidylcholine (DPMC), dipalmitoyl phosphatidylcholine (DPPC), distearoyl phosphatidylcholine (DSPC); dimyristoyl phosphatidic acid (DPMA), dipalmitoyl phosphatidic acid (DPPA), distearoyl phosphatidic acid (DSPA); dimyristoy! phosphatidyl ethanolamine (DPME), dipalmitoyl phosphatidyl ethanolamine (DPPE) and distearoyl phosphatidyl ethanolamine (DSPE). -
27. Use of a compound selected from the group consisting of MonoPhosphoryl Lipid A (MPL) and a L-Seryl Aminoalkyl Glucosaminide Phosphate compound (AGP), in the manufacture of a medicament for use in a method for ameliorating or substantially preventing an infectious disease, autoimmune disease or allergic condition in a subj ect comprising contacting the subject with an effective amount of the compound in the absence of exogenous antigen. Amended Sheet — 2004-03-30
28. Use of claim 27 wherein said L-Seryl Aminoalkyl Glucosaminide Phosphate compound is selected from the group consisting of RC-526, RC-554, RC-555, RC-537,RC-527, RC-538, RC-560 and RC-512.
29. Use of claim 27 wherein said L-Seryl Aminoalkyl Glucosaminide Phosphate compound is selected from the group consisting of RC-538, RC-560 and RC-
512.
30. Use in accordance with claim 1, wherein the compound is administered for modulating the production of cytokines.
31. Use in accordance with claim 1, wherein the compound is administered for modulating Toll-like receptor activity.
32. A pharmaceutical composition in accordance with claim 24, substantially as herein described. Amended Sheet — 2004-03-30
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20582000P | 2000-05-19 | 2000-05-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200209438B true ZA200209438B (en) | 2004-02-20 |
Family
ID=32849290
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200209438A ZA200209438B (en) | 2000-05-19 | 2002-11-20 | Prophylactic and therapeutic treatment of infectious autoimmune and allergic diseases with mono and disaccharide-base compounds. |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN1907289A (en) |
ZA (1) | ZA200209438B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9241988B2 (en) * | 2012-04-12 | 2016-01-26 | Avanti Polar Lipids, Inc. | Disaccharide synthetic lipid compounds and uses thereof |
CN104910206B (en) * | 2015-04-27 | 2017-01-18 | 国家海洋局第三海洋研究所 | Polyunsaturated fatty acyl phosphatide derivative and preparation method and application thereof |
-
2001
- 2001-05-18 CN CN 200610108035 patent/CN1907289A/en active Pending
-
2002
- 2002-11-20 ZA ZA200209438A patent/ZA200209438B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN1907289A (en) | 2007-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2007202117B2 (en) | Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds | |
AU2001269695A1 (en) | Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono and disaccharide-based compounds | |
US6911434B2 (en) | Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds | |
US8318697B2 (en) | Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds | |
EP1482955B1 (en) | Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds | |
US20080119415A1 (en) | Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds | |
ZA200209438B (en) | Prophylactic and therapeutic treatment of infectious autoimmune and allergic diseases with mono and disaccharide-base compounds. | |
RU2289410C2 (en) | Prophylaxis and treatment of infectious and other diseases by using compounds based on mono- n disaccharides | |
RU2288723C2 (en) | Preventive and therapeutic method for treating infectious and other diseases by applying immunoeffective compounds |